News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


Prognostic value of the MIB-1 labeling index for central neurocytomas


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www.neurology.org/cgi/content/abstract/62/6/987

Posted on: 03/26/2004

Prognostic value of the MIB-1 labeling index for central neurocytomas

Dirk Rades, MD, Steven E. Schild, MD and Fabian Fehlauer, MD

From the Department of Radiation Oncology (Drs. Rades and Fehlauer), University Hospital Hamburg–Eppendorf, Hamburg, Germany; and Department of Radiation Oncology (Dr. Schild), Mayo Clinic Scottsdale, AZ.

Address correspondence and reprint requests to Dr. D. Rades, Department of Radiation Oncology, University Hospital Hamburg–Eppendorf, Martinistr. 52, 20246 Hamburg, Germany; e-mail: Rades.Dirk@gmx.net

Although central neurocytomas are generally described as benign CNS lesions, malignant behavior including craniospinal dissemination and tumor-related death may occur. This meta-analysis was performed to investigate the prognostic value of the MIB-1 labeling index. Data were obtained not from the literature alone but also from contact with the authors. The data suggested an MIB-1 index score of >3% to be associated with a worse prognosis for local control (p < 0.0001) and survival (p = 0.0004).




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740